State Board of Administration of Florida Retirement System purchased a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) during the second quarter, according to its most recent filing with the SEC. The firm purchased 51,380 shares of the company’s stock, valued at approximately $547,000.
A number of other large investors have also bought and sold shares of the business. Worth Asset Management LLC acquired a new stake in shares of AbCellera Biologics during the first quarter worth $25,000. Banque Cantonale Vaudoise acquired a new position in shares of AbCellera Biologics in the second quarter worth approximately $67,000. Nisa Investment Advisors LLC acquired a new position in AbCellera Biologics in the second quarter valued at approximately $85,000. SG Americas Securities LLC acquired a new position in shares of AbCellera Biologics during the second quarter worth approximately $103,000. Finally, Gryphon Financial Partners LLC acquired a new position in shares of AbCellera Biologics during the first quarter worth approximately $102,000. 44.42% of the stock is owned by institutional investors.
AbCellera Biologics Trading Up 0.6 %
Shares of NASDAQ:ABCL opened at $14.16 on Friday. The stock has a fifty day simple moving average of $11.20 and a two-hundred day simple moving average of $10.37. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of 17.92 and a beta of -0.54. AbCellera Biologics Inc. has a 12-month low of $5.42 and a 12-month high of $15.90.
Analyst Upgrades and Downgrades
AbCellera Biologics Company Profile
AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
- Get a free copy of the StockNews.com research report on AbCellera Biologics (ABCL)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.